Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03723356 · ClinicalTrials.gov registry record
Linking Cognitive Functioning to Multimodal Imaging in Multiple Sclerosis (MS)
A clinical trial, sponsored by NYU Langone Health.
- Terminated
- Registry status
- 6
- Enrollment target
NCT03723356 is a clinical trial that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 6 participants.
The verdict
NCT03723356 was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- 6 participants
- Enrollment target
Study Summary
Multiple sclerosis (MS) is the most common progressive neurologic disorder to occur in adults of working-age. Despite longstanding recognition of cognitive impairment as a symptom of MS, two obstacles in measurement have limited understanding its biological basis, and therefore identifying targeted options for management. First is the absence of a sensitive and precise measure of cognitive impairment. Second is the absence of an index of disease status linked to brain pathophysiology and cognitive performance. This project overcomes both obstacles to link cognitive impairment to MS disease biomarkers. The absence of a sensitive and precise measure of cognitive impairment, along with the absence of an index of disease status linked to brain pathophysiology and cognitive performance, limits the understanding of the biological basis for multiple sclerosis (MS). This project overcomes both obstacles to link cognitive function to MS disease biomarkers, and provides preliminary evaluation of a disease modifying therapy (Tecfidera) for preserving cognitive function.
Interventions
- DIAGNOSTIC_TEST fMRI
- DIAGNOSTIC_TEST Siemens Biograph mMR (molecular MR)
- DIAGNOSTIC_TEST Diffusion Spectrum Imaging (DSI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2018-07-01 |
| Est. Completion | 2021-01-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03723356
The ClinicalTrials.gov registry entry for NCT03723356 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which fMRI is the first listed.
NCT03723356 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03723356 about?
NCT03723356 is a clinical study titled "Linking Cognitive Functioning to Multimodal Imaging in Multiple Sclerosis (MS)". Multiple sclerosis (MS) is the most common progressive neurologic disorder to occur in adults of working-age. Despite longstanding recognition of cognitive impairment as a symptom of MS, two obstacles in measurement have limited understanding its biological basis, and therefore identifying targeted ...
What is the current status of trial NCT03723356?
This trial is currently terminated. The enrollment target is 6 participants. The study started on 2018-07-01. Estimated completion is 2021-01-09.
What interventions are being tested in trial NCT03723356?
The interventions under investigation include: fMRI (DIAGNOSTIC_TEST), Siemens Biograph mMR (molecular MR) (DIAGNOSTIC_TEST), Diffusion Spectrum Imaging (DSI) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03723356?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.